Vir, awaiting ‘functional cure’ data for hep B combo, won’t take treatment forward alone
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner.
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner.
